报价延迟最少15分钟:2025/07/12 06:46 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.7 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.75/-1.10
|
|
企业价值
1.25B
|
| 资产负债 |
|
每股账面净值
1.10
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
113.31M
|
|
每股收益
0.24
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/12 06:46 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform,PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsindeficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease. |
